Early COVID-19 respiratory risk stratification using machine learning

Molly J Douglas,1,2 Brian W Bell,2 Adrienne Kinney,2 Sarah A Pungitore,2 Brian P Toner2

ABSTRACT

Background COVID-19 has strained healthcare systems globally. In this and future pandemics, providers with limited critical care experience must distinguish between moderately ill patients and those who will require aggressive care, particularly endotracheal intubation. We sought to develop a machine learning-informed Early COVID-19 Respiratory Risk Stratification (ECoRRS) score to assist in triage, by providing a prediction of intubation within the next 48 hours based on objective clinical parameters.

Methods Electronic health record data from 3447 COVID-19 hospitalizations, 20.7% including intubation, were extracted. 80% of these records were used as the derivation cohort. The validation cohort consisted of 20% of the total 3447 records. Multiple randomizations of the training and testing split were used to calculate confidence intervals. Data were binned into 4-hour blocks and labeled as cases of intubation or no intubation within the specified time frame. A LASSO (least absolute shrinkage and selection operator) regression model was tuned for sensitivity and sparsity.

Results Six highly predictive parameters were identified, the most significant being fraction of inspired oxygen. The model achieved an area under the receiver operating characteristic curve of 0.789 (95% CI 0.785 to 0.812). At 90% sensitivity, the negative predictive value was 0.997.

Discussion The ECoRRS score enables non-specialists to identify patients with COVID-19 at risk of intubation within 48 hours with minimal undertriage and enables health systems to forecast new COVID-19 ventilator needs up to 48 hours in advance.

Level of evidence IV.

INTRODUCTION

The COVID-19 global pandemic has caused unprecedented levels of population illness and healthcare resource utilization.1–4 Infection with the causative agent of COVID-19, SARS-CoV-2, can range from asymptomatic5–6 to life-threatening,7–8 and illness requiring mechanical ventilation carries a high mortality rate of 25% to 60%9–10. The combination of heavy illness burden and finite resources has made triage a necessity in many health systems, with a particular strain on intensive care units (ICUs).1,11 Patients with acute respiratory failure may require endotracheal intubation and placement on a ventilator for respiratory support, interventions which are only performed in an ICU setting. Appropriate triage can reduce unnecessary ICU admissions and promote allocation of resources to the sickest patients. Factors shown to be associated with severe COVID-19 include advanced age,12–13 cardiovascular disease, chronic kidney disease, diabetes, and laboratory findings such as lymphopenia, thrombocytopenia, and elevated inflammatory markers.14–18

Machine learning has been used to further the understanding of COVID-19, including for disease diagnosis19–26 and transmission.27–30 Further, an April 2020 systematic review by Wynants et al31 discussed 50 published models for predicting disease progression or severity, but recommended none for clinical practice due methodological limitations including small sample sizes, inadequate training versus testing cohorts, or other factors leading to high risk of bias or limited external validity. A January 2021 review of artificial intelligence (AI) applications for COVID-19 by Tayarani et al32 reviewed 14 additional studies of machine learning for predicting COVID-19 severity and found promise in works using demographics, laboratory values, and other electronic health record (EHR) data. Online calculators have been published with some studies.33–36

However, there remains a lack of standardization on how to predict an individual’s disease trajectory and risk of severe illness. Thus, assessing the relative weight of risk factors in any particular patient’s case has remained largely a provider-level task. Our goal in this work is to develop a tool to aid in risk assessment for progression to severe disease. Specifically, we aimed to analyze demographic and clinical data with statistical and machine learning techniques, and to develop a prediction score, usable
at the bedside by non-experts, to stratify the risk of progression to intubation within the next 48 hours for patients hospitalized with COVID-19.

METHODS

Methods and results are reported in accordance with the 2015 statement for Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis.32

Data source

De-identified patient-level data were provided via a hospital-affiliated clinical data warehouse. Patients testing positive for SARS-CoV-2 at three academic medical centers in Arizona between January and April 2020 were included. Extracted variables included age, sex, vital signs, laboratory values (including blood counts, electrolytes, blood gas results, and inflammatory markers), oxygen requirements, and timing of intubation.

Patient comorbidities were extracted to describe the study cohort. However, knowledge of comorbidities is dependent on prior interaction with the healthcare system and on patient reporting or availability of medical records. This information may be unavailable at the urgent point of care. Accordingly, comorbidity information was omitted from model training to build a score robust to the incomplete data that may be available in times of health system crisis. Further, data on self-identification of race and ethnicity were not reliably available within the electronic medical record (EMR), so race and ethnicity were not considered in modeling.

Data preprocessing and missing data

Data were reformatted into 4-hour time blocks (rows). A 4-hour interval was chosen to match the frequency of routine vital sign checks in non-ICU units, representing the highest data sampling rate that was likely to be available across the population. Vital signs were then summarized as mean, minimum, and maximum for each block, as well as the initial value recorded on presentation for each patient. Laboratory values, measured less frequently, were represented as current and initial values. Respiratory support other than intubation was quantified by fraction of inspired oxygen (FiO₂) and oxygen delivery device (ie, nasal cannula, face mask, high-flow humidified cannula, etc). Where necessary, FiO₂ was estimated as 0.21 (room air) plus an additional 0.04 for every 1 L/min increase in oxygen flow rate.33 Each “row” (4-hour block) was labeled with whether the patient required intubation within the subsequent 48 hours, as well as the number of hours from the end of that time block until the time of their intubation. Where values were missing, the last measured vital signs were carried forward for up to 12 hours and the laboratory values for up to 72 hours. Otherwise, missing fields were left blank. Rows with greater than 85% missing values were excluded. Parameters were excluded from modeling if they were populated in fewer than 15% of rows. This left 67 parameters for use in model training, including the initial and summary values as separate model inputs. Bivariate comparisons between the intubated and non-intubated groups were done using the χ² test for categorical data and the Mann-Whitney U test for continuous data. A complete list of the parameters initially considered in modeling, prior to elimination of those with low prevalence in the data set, is available in the online supplemental information. Finally, the data were randomly split into 80% training and 20% testing sets.

Modeling

The primary outcome used in model development was whether or not the patient was intubated within 48 hours of the end of each 4-hour time block. A patient’s physiological state during each time block was considered as a separate model input, such that each “row” formed an independent training example. Model performance was assessed by the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and qualitatively for ease of application in clinical practice.

LASSO regression

A least absolute shrinkage and selection operator (LASSO) regularized linear regression model was trained.34 The regularization parameter α had little impact on AUC, but affected the number of non-zero weights (sparsity) and specificity of the model. We noted a sharp drop in specificity as α approached 1, so α=0.1 was selected to minimize the number of non-zero weights without sacrificing specificity. This resulted in the inclusion of 10 to 15 predictors, depending on the training and testing data split. Feature importance was then explored by rerunning the model across 100 randomizations of the training and testing data split. Thirteen parameters were used in >50% of model runs, and these were then used in an elimination algorithm where model performance was tested after dropping each parameter in turn (Figure 1). Features with minimal (<0.002) reduction in AUC or with high potential for clinical redundancy (such as current temperature and maximum temperature) were removed, leaving only seven predictors: fraction of inspired oxygen (FiO₂), initial red blood cell count (RBC_initial), maximum oxygen saturation for the 4-hour block (SpO₂_max), lymphocyte count (lymph#), initial modified Sequential Organ Failure Assessment score (mSOFA_initial), current temperature (temp), and body weight (weight). LASSO was run again with just these seven predictors, and...
all predictors except mSOFA_initial had non-zero coefficient values, resulting in a model with just six predictors.

Model performance was then assessed on the testing cohort. The CIs for LASSO performance were bootstrapped using the empirical bootstrap, where the testing set was resampled with replacement 1000 times, and 95% confidence bands were calculated and plotted using the simultaneous joint confidence regions method.

**XGBoost**

An eXtreme Gradient Boosting (XGBoost) model was trained. Model tuning initially focused on sensitivity and sparsity. Bracketing algorithms were used to select the optimal values for scale_pos_weight (to more heavily weight cases of intubation, given the preponderance of negative examples in the data set), maximum tree depth (to optimize model complexity), as well as the regularization parameter $\gamma$. Given the goal of a bedside usable prediction score, we initially focused on building a single-tree model. However, this yielded performance inferior to LASSO regression, with an AUC of 0.74, sensitivity of 0.88, and specificity of 0.60, so a more complex model using 100 trees was tuned. Tuning this model for maximum sensitivity rather than sparsity ($\gamma=0$) yielded a model with improved performance, as described in the Results section. Feature importance was explored by gain in model performance.

**RESULTS**

**Cohort**

There were 3447 patient encounters meeting the inclusion criteria, of which 20.7% required intubation. The baseline cohort characteristics regarding comorbidities and all parameters used in model training are presented in table 1. After

---

**Table 1**  
Cohort initial characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (N=3447)</th>
<th>Not intubated (n=2733)</th>
<th>Intubated (n=714)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>49.4</td>
<td>47.0</td>
<td>58.4</td>
<td>0.01</td>
</tr>
<tr>
<td>Percent female</td>
<td>51.5</td>
<td>54.3</td>
<td>40.6</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>89.3</td>
<td>89.2</td>
<td>89.6</td>
<td>0.37</td>
</tr>
<tr>
<td>Body mass index</td>
<td>32.8</td>
<td>32.6</td>
<td>33.6</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Comorbidities (not used in modeling)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary Disease (%)</td>
<td>7.9</td>
<td>6.1</td>
<td>14.8</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Asthma (%)</td>
<td>13.3</td>
<td>13.3</td>
<td>13.3</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Heart failure (%)</td>
<td>11.3</td>
<td>7.2</td>
<td>26.9</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>34.7</td>
<td>29.4</td>
<td>54.9</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Labs and vital signs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td>0.65</td>
<td>0.64</td>
<td>0.69</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>24.33</td>
<td>23.60</td>
<td>27.14</td>
<td>0.40</td>
</tr>
<tr>
<td>BUN:creatinine ratio</td>
<td>23.85</td>
<td>23.55</td>
<td>25.01</td>
<td>0.02</td>
</tr>
<tr>
<td>Calcium (mg/dL)</td>
<td>8.68</td>
<td>8.73</td>
<td>8.49</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Chloride (mEq/L)</td>
<td>101.38</td>
<td>101.42</td>
<td>101.25</td>
<td>0.01</td>
</tr>
<tr>
<td>D-dimer (ng/mL)</td>
<td>188.57</td>
<td>173.81</td>
<td>245.09</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Fraction of inspired oxygen (%)</td>
<td>58.96</td>
<td>59.05</td>
<td>58.63</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Glasgow Coma Scale</td>
<td>13.39</td>
<td>13.68</td>
<td>12.29</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Glomerular filtration rate (mL/min)</td>
<td>82.09</td>
<td>83.27</td>
<td>77.59</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>146.36</td>
<td>143.33</td>
<td>157.98</td>
<td>0.35</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>35.86</td>
<td>35.67</td>
<td>36.61</td>
<td>0.01</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>11.83</td>
<td>11.77</td>
<td>12.06</td>
<td>0.03</td>
</tr>
<tr>
<td>Lymphocyte count (10^9/L)</td>
<td>1.29</td>
<td>1.32</td>
<td>1.17</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>16.40</td>
<td>17.15</td>
<td>13.52</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin (g/dL)</td>
<td>29.26</td>
<td>29.26</td>
<td>29.24</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin concentration (g/dL)</td>
<td>32.53</td>
<td>32.55</td>
<td>32.46</td>
<td>0.46</td>
</tr>
<tr>
<td>Mean corpuscular volume (fL)</td>
<td>89.88</td>
<td>89.84</td>
<td>90.01</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Mean platelet volume (fL)</td>
<td>10.52</td>
<td>10.51</td>
<td>10.58</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>mSOFA score</td>
<td>3.62</td>
<td>3.18</td>
<td>5.30</td>
<td>0.28</td>
</tr>
<tr>
<td>Oxygen saturation (%)</td>
<td>93.85</td>
<td>93.93</td>
<td>93.54</td>
<td>0.16</td>
</tr>
<tr>
<td>Platelet count (10^9/L)</td>
<td>257.96</td>
<td>257.30</td>
<td>260.48</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Red blood cell count (10^12/L)</td>
<td>4.07</td>
<td>4.06</td>
<td>4.09</td>
<td>0.35</td>
</tr>
<tr>
<td>Red cell distribution (%)</td>
<td>14.76</td>
<td>14.80</td>
<td>14.62</td>
<td>0.02</td>
</tr>
<tr>
<td>Red cell distribution width, SD (fL)</td>
<td>47.86</td>
<td>47.95</td>
<td>47.50</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Temperature (°F)</td>
<td>98.42</td>
<td>98.40</td>
<td>98.50</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>White cell count (thousand/µL)</td>
<td>89.24</td>
<td>89.15</td>
<td>89.57</td>
<td>0.37</td>
</tr>
</tbody>
</table>

The table shows the distribution of comorbidities and mean initial physiological metrics used in model training for the overall cohort, intubated patients and non-intubated patients.

BUN, blood urea nitrogen; mSOFA, modified Sequential Organ Failure Assessment.
data preprocessing as discussed in the Methods section, the average missing data rate was 57% across the 4-hour time blocks, with an SD of 30%. We considered all patients who did not have a documented intubation to be in the non-intubated cohort, so there were no unclassified patients with respect to intubation.

LASSO regression
LASSO modeling, optimized for sensitivity and sparsity (ie, minimization of the number of inputs required), yielded an AUC of 0.798, with 95% CI of 0.785 to 0.812 (figure 2). At the 90% sensitivity operating point, we observed a specificity of 61.7% (95% CI 0.524 to 0.710), NPV of 0.997 (95% CI 0.996 to 0.998), and PPV of 0.040 (95% CI 0.033 to 0.047). The six parameters included in the final LASSO model were FiO₂, RBC_initial, SpO₂_max, lymph#, current temperature (temp), and body weight (weight). The relative weights of each predictor are shown in figure 3. FiO₂ was the most significant predictor, followed by maximum oxygen saturation (SpO₂). The score is calculated by summing the value of each predictor multiplied by its coefficient and adding the constant (C0). If necessary, FiO₂ is estimated as 0.21 (room air) plus an additional 0.04 for each 1 L/min increase in oxygen flow rate. Positive values predict intubation within the next 48 hours, and negative values predict no intubation within the next 48 hours. The greater the magnitude of the score, the greater the certainty of the prediction.

XGBoost
XGBoost classification tree modeling, optimized for sensitivity and trained on all parameters in the data set, yielded an AUC of 0.86, with a sensitivity of 0.99 at a specificity of 0.74. The NPV was 0.999 and the PPV was 0.082. Of the parameters, FiO₂ was consistently the most important by gain in model performance. The final model used 100 unique trees which combine to produce the prediction. A subsection of one of these tree diagrams is shown in figure 4.

Early COVID-19 Respiratory Risk Stratification prediction score
Both models were highly unlikely to undertriage patients, with NPV of 99.7% (LASSO) and 99.9% (XGBoost). The XGBoost model, however, achieved approximately double the PPV of LASSO and thus is less likely to overtriage patients (ie, indicate a need for intubation when the patient will not be intubated within the specified time frame). Given its complexity, the XGBoost model would require clinicians to enter a large number of variables into a specialized software program to see a prediction; this presents a significant barrier to rapid deployment for emergency triage. In contrast, the LASSO model, with only six parameters, can be used by any practitioner with a simple calculator or spreadsheet program. Thus, we present the LASSO model as the Early COVID-19 Respiratory Risk Stratification (ECoRRS) score. The coefficients and constant to calculate the ECoRRS score are shown in table 2. Positive results predict the need for intubation within 48 hours, and negative results predict no intubation within that time frame. The greater the magnitude of the score, the greater the certainty of the prediction.

DISCUSSION
We analyzed EHR data with two methods, LASSO regularized linear regression and XGBoost classification trees, to predict intubation within the next 48 hours for patients hospitalized with COVID-19. Both models achieved high sensitivity and very low rates of undertriage. XGBoost performed as well or better on all metrics compared with LASSO. However, given the marked simplicity and sparsity of LASSO relative to XGBoost, the LASSO model, which uses six objective inputs, is presented as the ECoRRS score.
The ECoRRS score can be used to predict intubation and forecast resource utilization up to 48 hours in advance, which has implications for both individual patient care and for system-wide planning and staffing. The score tolerates overtriage to maximize sensitivity, identifying a subpopulation “at risk” of intubation. At the system level, however, hospitals can multiply the number of patients scoring positive on ECoRRS by the model’s PPV and arrive at a relatively precise estimate of the number of inpatients likely to newly require a ventilator within the next 48 hours. This can facilitate timely redistribution of staff and resources to the areas of greatest need.

With regard to individual patient care, our framework relies on objective measurements and not patient history or comorbidities, which may be unavailable at the urgent point of care. Additionally, relying on objective measures, rather than subjective assessments by healthcare providers, supports the utility of ECoRRS as a triage tool for use by personnel with minimal healthcare training when systems are overburdened.

Multiple other investigators have sought to develop predictive algorithms for COVID-19 disease severity. Notably, Marcos and colleagues developed an open-source online calculator using just nine variables to classify patients as high or low risk for severe disease, using a methodology similar to that presented here. Our model differs in that it provides prediction of intubation specifically within a 48-hour window and does not rely on knowledge of comorbidities to predict disease trajectory.

This study has multiple limitations. First, the indications for intubation were not protocolized and the decision to intubate was at the treating clinician’s discretion. Thus, differences in individual practice may have impacted the study's results. Further, COVID-19 treatment has evolved since our data collection period (January–April 2020). Prone positioning, which has historically been used as an adjunct for intubated patients with severe acute respiratory distress syndrome, came into practice to improve oxygenation in non-intubated patients with COVID-19. Proning increased in popularity during our study period, but data on the precise rate and intensity of proning in our cohort were not available. Studies have shown that prone positioning improves oxygenation and possibly reduces mortality in COVID-19, but it is not clearly associated with a reduced need for intubation. As the most powerful predictor of need for intubation in our cohort was FiO₂, it is likely that the benefits of proning would be reflected in FiO₂ requirements, allowing the score to remain useful with increased utilization of prone positioning.

Additionally, remdesivir was introduced for COVID-19 under emergency use authorization in May 2020 and full US Food and Drug Administration approval followed in October 2020. However, subsequent studies have shown minimal impact of this drug on disease trajectory, and we suspect remdesivir’s introduction to have little impact on the ECoRRS score’s generalizability. Convalescent plasma was also introduced in Spring 2020 with significant hopes for modifying disease progression, although large trials subsequently found this treatment too was ineffective. In contrast, glucocorticoids in patients requiring supplemental oxygen became standard of care during our study period, after the RECOVERY trial. The impact of this major therapeutic is likely captured only in the latter half of our cohort.

Further, our data source is linked to both strengths and significant limitations. With assistance from a hospital-affiliated clinical data warehouse, we extracted real-world EHR data. Such data are notoriously challenging and often include high rates of missing or incorrect values. Our average missing data rate of 57% is similar to that reported in previously reported studies, including an evaluation of blood pressure documentation in the EHR which was found to vary in missing rate from 0.1% to 52%. These missing data may have led to bias in our conclusions and model performance. However, it also may reflect incomplete information that healthcare workers operate with on a regular basis.

Finally, our 3447 patients were from three academic hospitals located within the same state. Validation studies in a wider multi-center cohort are needed to better assess the external validity of the ECoRRS score. The authors plan to undertake this using data from geographically diverse and non-academic hospitals within the same health network, which spans 6 states and 30 facilities.

The contrast of the user-friendliness of the LASSO model versus the accuracy of the XGBoost model highlights an active challenge in healthcare machine learning and informatics. Although numerous algorithms have been developed for healthcare, few have been deployed in the clinical setting, leading some to question the hopes for AI in medicine. Although EHR systems remain closed environments, the use of novel algorithms will require clinicians to manually enter data into a secondary

### Table 2

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>FiO₂ (as fraction)</td>
<td>7.060x10⁻¹</td>
</tr>
<tr>
<td>Initial red blood count (million/µL)</td>
<td>1.950x10⁻²</td>
</tr>
<tr>
<td>SpO₂ max (%)</td>
<td>1.045x10⁻⁴</td>
</tr>
<tr>
<td>Current lymphocyte count (thousand/µL)</td>
<td>6.765x10⁻⁵</td>
</tr>
<tr>
<td>Temperature (°C)</td>
<td>2.955x10⁻⁵</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>−1.117x10⁻⁵</td>
</tr>
<tr>
<td>Constant (C0)</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Based on the LASSO model, the score is calculated by summing the value of each predictor multiplied by its coefficient and adding the constant (C0). If necessary, FiO₂ is estimated as 0.21 (room air) plus an additional 0.04 for each 1 L/min increase in oxygen flow rate. Positive values predict intubation within the next 48 hours, and negative values predict no intubation within the next 48 hours. The greater the magnitude of the score, the greater the certainty of the prediction. ECoRRS, Early COVID-19 Respiratory Risk Stratification; FiO₂, fraction of inspired oxygen; SpO₂ max, maximum oxygen saturation for the 4-hour block.
CONCLUSION

The ECoRRS score enables non-specialists to identify patients with COVID-19 at risk of intubation within 48 hours with minimal undertriage and enables health systems to forecast new COVID-19 ventilator needs up to 48 hours in advance.

Acknowledgements

This research made use of the community-developed core Python and Julia packages, including Pyton (Perez and Granger), Scikit-learn (Fabián et al), SciPy (Eric et al), and Pandas (Wes and Wes). This work would not have been possible without the team at the University of Arizona’s Clinical Research Data Warehouse, who worked closely with us on clinical data extraction and de-identification.

Contributors

MJD, BPT: development of the research question, data acquisition and cleaning, data analysis, article preparation. BWB: development of the research question, data acquisition and cleaning, data analysis. AK: data acquisition and cleaning, data analysis. SAP: data acquisition and cleaning, data analysis, article preparation. Author guarantor: MJD

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Patient consent for publication

Not required.

Ethics approval

This study involves human participants but the University of Arizona Institutional Review Board exempted this study (protocol number 2004546291). This was a retrospective study using chart review only. There was no interaction with or impact on care received among the study participants. The study was deemed “non-human subjects research” by the University of Arizona Institutional Review Board.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data may be obtained from a third party and are not publicly available. The data set generated and analyzed in the current study is protected by a Banner Health data use agreement (DUA), which prohibits placing the data in a public repository. The institution requires approval of a new DUA with any individual wishing to access the data. Requests for data access may be directed to the corresponding author, who will facilitate the request for a DUA through Banner Health. New requests typically require 3 to 6 months to process.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and it is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Molly J Douglas http://orcid.org/0000-0002-2567-3274

REFERENCES


39 India.

38 2013;368:2159–68.


36 2016.

35 BMJ


